Amneal Pharmaceuticals, Inc. (AMRX)

収益の仕組み

Amneal earns revenue by selling pills, injectables and other finished medicines by the unit. Generic and specialty products go mainly through the big drug wholesalers, retail chains, mail-order pharmacies, group purchasing organisations and directly to hospitals; AvKARE sells to federal agencies under government contracts and to retail and institutional customers. Gross list prices are heavily reduced by chargebacks, rebates and sales allowances, so reported net revenue is what remains after those deductions. There is no subscription or recurring-fee element: each dollar has to be re-won on the next order, and for generics the price of a given molecule normally falls as more competitors are approved. FY2025 net revenue was $3,018.8 million, up 8.0% on 2024, with gross profit of $1,113.3 million.

セグメント別売上高

Amneal's advantage is industrial rather than commercial: vertically integrated manufacturing across the US, India and Ireland, a very broad catalogue of more than 280 product families, and a pipeline deliberately tilted towards harder-to-copy forms — 95% of the 43 products in development are non-oral-solid, and the company describes injectables and biosimilars as its priority. Hard-to-manufacture products attract fewer competitors and hold price longer. But this is a narrow moat at best. The 10-K states plainly that as competitors introduce their own generic equivalents, revenue and gross margin from those products generally decline, often rapidly, and that the company cannot control the timing or number of entrants. There is no pricing power, no switching cost for a wholesaler, and the branded Specialty products are protected only by patents and exclusivity periods that expire — an authorized generic of RYTARY was launched in 2025.

The underlying demand is about as recession-proof as it gets: people take medicines for Parkinson's, hypothyroidism or an infection whether or not the economy is growing, and generics are the cheap option that health systems push towards in hard times. Volumes track prescriptions, ageing and the patent-expiry calendar — a wave of drugs losing exclusivity creates new markets to enter — rather than the business cycle. What moves Amneal's results is therefore not the economy but competitive intensity: how many rivals win FDA approval for the same molecule, how fast prices fall, and how many new launches land in a given year. Two segment-specific swings matter too: the Specialty business depends on individual branded products that lose most of their value once generics arrive, and AvKARE depends on US federal purchasing, which the 10-K notes can be disrupted by government shutdowns or spending freezes.

主なリスク

• Price erosion as competitors launch the same generic — The company discloses that as competitors introduce their own generic equivalents of its products, revenue and gross margin from those products generally decline, often rapidly. It also lists authorized generics launched by brand companies and the general price competition of the industry as factors that could significantly limit growth.
• Revenue concentrated in a few products — The 10-K states that a substantial portion of total revenue is expected to keep coming from a limited number of products: for the year ended December 31, 2025 the top five product families across Affordable Medicines and Specialty accounted for 25% of consolidated net revenue.
• Dependence on four customers and further customer consolidation — Cencora, McKesson, Cardinal Health and CVS Health together accounted for roughly 71% of total net product sales in 2025 (70% in both 2024 and 2023). Amneal says it has no long-term agreements guaranteeing future business with any major customer, and warns separately that further consolidation among customers could depress both volumes and prices.
• Manufacturing quality and site concentration — Manufacturing or quality control problems could damage the company's reputation, force costly remedial work and hurt results. A related risk factor notes that the majority of products are made at a limited number of locations, so an interruption at one site or in the supply chain could have a material adverse effect.
• Substantial indebtedness — As of December 31, 2025 total indebtedness was $2.7 billion — $2.1 billion on the Term Loan Due 2032 and $600.0 million of 6.875% senior secured notes due 2032. The company expects to pay $193.9 million of interest during 2026 and warns it may not generate enough cash to service all its debt; credit agreement terms also restrict how it can respond to change.
• Litigation, including opioid and intellectual property cases — Amneal manufactures and derives part of its revenue from opioid-class products and is party to civil prescription opioid litigation. It also flags that competitors may allege patent infringement, with possible losses tied to 'at-risk' product launches, and that legal proceedings generally may require substantial expense to defend.
• Regulatory approvals, reimbursement and government contracting — Approvals for new generics may be delayed or become harder to obtain if the FDA changes its requirements. Healthcare reform and reductions in coverage or reimbursement by public payers, HMOs and other third parties may hurt the business, and failure to comply with government contracting rules — relevant to the AvKARE segment — or a US government shutdown could damage regulatory, operational and financial performance.

主要顧客が売上高の71%を占める

Four customers — Cencora, McKesson Drug Co., Cardinal Health and CVS Health — collectively accounted for approximately 71% of consolidated net revenue for the year ended December 31, 2025, against 70% in each of 2024 and 2023. Amneal has around 1,300 customers in total, over 1,100 of them inside the AvKARE segment, but the tail is small in dollar terms. The company states it holds no long-term agreements guaranteeing future business with any major customer, so the loss of one, or a reduction in its orders, could materially affect results.